Uncovered Translation Pathway Unveils How Cancer Cells Accelerate KRAS Production

Cancer cells possess a remarkable ability to hijack cellular machinery to accelerate their own growth and evade targeted treatments. Scientists have now uncovered a hidden mechanism within the translation pathway that allows tumors to rapidly produce KRAS, a notorious cancer-driving protein. The discovery exposes a fundamental vulnerability in treatment-resistant tumors.[1][5]

The findings, published October 29, 2026, in the journal Nature Cell Biology, reveal how a specific chemical tag alters the speed at which genetic instructions are decoded. The research demonstrates that the translation elongation machinery harbors intrinsic mechanisms that selectively shape the cancer proteome. This challenges the long-held assumption that protein synthesis occurs at uniform rates.[1][4]

The international collaboration involved researchers from five institutions, including St. Jude Children's Research Hospital, the Karolinska Institute, McGill University, Stanford University, and the University of Texas MD Anderson Cancer Center. The team focused on eEF1A, a translation elongation factor that governs the speed and accuracy with which ribosomes read messenger RNA.[1][5]

The METTL13 Methylation Axis

To build a protein, the ribosome reads three-letter genetic sequences known as codons. The researchers found that an enzyme called METTL13 adds a methyl tag to eEF1A at a specific site known as lysine 55. This dimethylation, abbreviated as eEF1AK55me2, acts as a selective accelerator for specific genetic sequences.[1][5]

This chemical modification does not simply speed up all protein synthesis in bulk. Instead, it selectively enhances the decoding of rare, underrepresented codons that feature weak wobble-position base pairing. These specific codons happen to be heavily enriched in oncogenes like KRAS, giving the tumor a distinct growth advantage.[1][3]

To prove that the codon usage was the critical factor, the researchers performed a synonymous recoding experiment. They altered the KRAS genetic sequence in cancer cells, replacing the eEF1AK55me2-dependent codons with independent ones that code for the exact same amino acids. This subtle genetic edit completely reversed the effects of METTL13 depletion.[1][3]

When the KRAS messenger RNA was recoded to avoid the rare codons, knocking out METTL13 no longer stopped the cancer cells from producing the oncogenic protein. This confirmed that the translation machinery's intrinsic chemistry is directly linked to the proteomic identity of the cancer cell, rather than acting as a general on-switch.[1][3]

"There is a growing understanding that protein synthesis occurs at rates that are not uniform across the entire messenger RNA transcript," said Scott Blanchard, co-corresponding author from the St. Jude Department of Structural Biology.[5]

"When METTL13 is present and eEF1A K55 is methylated, the two related codons are decoded at very similar rates; when METTL13 is absent, the codons are decoded at different rates," Blanchard explained. This kinetic shift allows cancer cells to rapidly translate the KRAS messenger RNA that would otherwise stall the ribosome.[5]

Overcoming KRAS Inhibitor Resistance

KRAS mutations are primary drivers of two highly aggressive malignancies: lung adenocarcinoma and pancreatic ductal adenocarcinoma. While targeted therapies like the KRAS G12C inhibitor sotorasib have reached the clinic, tumors frequently develop resistance. The newly discovered METTL13 pathway appears to be a major engine behind this clinical resistance.[1][6]

In preclinical models of lung adenocarcinoma, tumors that were resistant to sotorasib relied heavily on the METTL13-driven translation pathway to maintain their oncogenic protein levels. By knocking out METTL13, the researchers were able to reduce the translation of KRAS messenger RNA and severely inhibit the growth of these resistant tumors.[1][6]

Crucially, disrupting the METTL13 enzyme in healthy preclinical models resulted in zero toxic side effects. This favorable safety profile suggests that targeting the methyltransferase could be a viable therapeutic strategy, as healthy cells do not depend on the eEF1AK55me2 modification to the same extreme degree that KRAS-driven cancer cells do.[5][6]

"Reducing KRAS production, a known driver of many cancers, can be achieved by knocking down METTL13 using a drug or some other mechanism, so that KRAS-driven cancer patients can have a better chance of survival," Blanchard noted. This approach could sensitize relapsed tumors to existing targeted therapies.[5]

The discovery also highlights a broader vulnerability in how tumors manage their heightened translational demands. Because oncogene-driven cancers require massive amounts of protein synthesis to sustain rapid cell division, they become uniquely dependent on auxiliary factors like METTL13 to clear translational bottlenecks that normal cells rarely encounter.[1][7]

Clinical Prognosis and Next Steps

To validate the clinical relevance of the eEF1AK55me2 axis, the research team examined patient outcome data. They found that high levels of METTL13 amplification in patients with lung and pancreatic adenocarcinomas strongly correlated with poor overall survival rates. The translation factor essentially serves as a biomarker for aggressive disease.[1][6]

Furthermore, among clinical trial patients treated with the KRAS G12C inhibitor adagrasib, inferred METTL13 activity was directly associated with an inferior clinical response. Tumors with the highest methylation activity were the most capable of buffering against the drug, maintaining enough KRAS protein synthesis to survive the pharmacological blockade.[1][3]

The work builds upon a foundational 2023 study by the same St. Jude team, which used cryo-electron microscopy to determine the atomic structure of human ribosomes bound to eEF1A. By combining that structural data with single-molecule fluorescence imaging, the researchers have now mapped the exact kinetic impact of the lysine 55 modification.[5]

Future research will likely focus on developing specific pharmacological inhibitors of METTL13. If a drug can safely block this methylation in human patients, it could provide a universal combination agent to deploy alongside KRAS inhibitors, cutting off the tumor's protein supply line before resistance can take root.[7]